Depomed receives favorable Markman ruling in Gralise patent litigation

Depomed announced a favorable "Markman" claim construction ruling by the U.S. District Court for the District of New Jersey in Depomed's ongoing patent infringement case against filers of three Abbreviated New Drug Applications seeking to market generic versions of Depomed's Gralise (gabapentin) product prior to the expiration of Depomed's patents listed for Gralise in the FDA's Orange Book. In a Markman ruling, the court determines the meaning of disputed patent terms at issue in patent litigation.